Single-tablet regimens in HIV: does it really make a difference?

References

• Goicoechea M, Best B. Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? Expert Opin Pharmacother 2007;8:371-82
   PubMed Web of Science ®Google Scholar
• Mathias A, Hinkle J, Menning M, et al. Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. J Acquir Immune Defic Syndr 2007;46:167-73
   PubMed Web of Science ®Google Scholar
• Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Preference and Adherence 2010;4:115-25
   PubMed Web of Science ®Google Scholar
• Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008;22:1951-60
   PubMed Web of Science ®Google Scholar
• Kilingley B, Pozniak A. The first once-daily single-tablet regimen for the treatment of HIV-infected patients. Drugs Today 2007;43:427-42
   PubMed Web of Science ®Google Scholar
• Boyd MA. Improvements in antiretroviral therapy outcomes over calendar time. Curr Opin HIV AIDS 2009;4:194-9
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011;204:1191-201
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Ragland K, Monk A, et al. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 2010;24:2835-40
   PubMed Web of Science ®Google Scholar
• Hodder SL, Mounzer K, DeJesus E, et al. Patient-reported outcomes in virologically suppressed, HIV-1-infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care and STDs 2010;24:87-96
   PubMed Web of Science ®Google Scholar
• The European AIDS Clinical Society Guidelines. Version 6.1. European AIDS Clinical Society (EACS). Paris: EACS, November 2012. Available at: http://www.europeanaidsclinicalsociety.org/index.php?option=com_content&view=article&id=59:eacs-guidelines&catid=37:guidelines&Itemid=41 [Last accessed July 2013]
   Google Scholar
• Thompson MA, Aberg JA, Hoy J, et al. IAS-USA Panel. Antiretroviral treatment of adult HIV infection – 2012 recommendations of the International AIDS Society–USA panel. JAMA 2012;308:387-402
   PubMed Web of Science ®Google Scholar
• Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Panel on Antiretroviral Guidelines for Adults and Adolescents. US: Department of Health and Human Services/AIDS Info, 12th February 2013. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Last accessed May 2013]
   Google Scholar
• Statement released on HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. US: Department of Health and Human Services/AIDS Info, 18th September 2012. Available at: http://aidsinfo.nih.gov/e-news/archive/2012/9/18 [Last accessed April 2013]
   Google Scholar
• Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection – recommendations for a public health approach. World Health Organization (WHO), June 2013. Available at: http://www.who.int/hiv/pub/guidelines/arv2013/en/ [Last accessed September 2013]
   Google Scholar
• Atripla – summary of product characteristics. European Medicines Agency (EMA). London: EMA, 4th October 2011. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000797/human_med_000657.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124 [Last accessed July 2013]
   Google Scholar
• Molina J-M, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011;378:238-46
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011;378:229-37
   PubMed Web of Science ®Google Scholar
• Stribild – summary of product characteristics. European Medicines Agency (EMA). London: EMA, 13th June 2013. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002574/human_med_001654.jsp&mid=WC0b01ac058001d124 [Last accessed July 2013]
   Google Scholar
• Cohen C, Davis K, Meyers J. Association of partial adherence to antiretroviral therapy with hospitalizations and healthcare costs in an HIV population. J Int AIDS Soc 2012;15:18060.
   PubMedGoogle Scholar
• Vera J, Aragão F, Guimarães M, et al. Benefits of ART simplification on adherence, clinical and economic outcomes. J Int AIDS Soc 2012;15:18064.
   Google Scholar
• Llibre JM, Antela A, Arribas JR, et al. El papel de las combinaciones de antirretrovirales a dosis fijas en el tratamiento de la infección por VIH-1. Enferm Infecc Microbiol Clin 2010;28:615-20
   PubMedGoogle Scholar
• Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011;53:1120-6
   PubMed Web of Science ®Google Scholar
• Deeks ED, Perry CM. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection. Drugs 2010;70:2315-38
   PubMed Web of Science ®Google Scholar
• Mathias A, Menning M, Wiser L, et al. Bioequivalence of the emtricitabine/rilpivirine/tenofovir disoproxil fumarate single tablet regimen. J Bioequiv Availab 2012;4:100-5
   Google Scholar
• Schrijvers R, Desimmie BA, Debyser Z. Rilpivirine: a step forward in tailored HIV treatment. Lancet 2011;378:201-3
   PubMed Web of Science ®Google Scholar
• Eviplera – summary of product characteristics. European Medicines Agency (EMA). London: EMA, 16th April 2013. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002312/human_med_001514.jsp&mid=WC0b01ac058001d124 [Last accessed July 2013]
   Google Scholar
• Olin JL, Spooner LM, Klibanov OM. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment. Ann Pharmacother 2012;46:1671-7
   PubMed Web of Science ®Google Scholar
• German P, Warren D, West S, et al. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010;55:323-9.
   PubMed Web of Science ®Google Scholar
• Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011;25:F7-12
   PubMed Web of Science ®Google Scholar
• Elion R, Gathe J, Rashbaum B, et al. The single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; ‘QUAD’) maintains a high rate of virologic suppression, and cobicistat (COBI) is an effective pharmacoenhancer through 48 weeks. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2010, Boston, USA. PH-938-B. Available at: http://hivandhepatitis.com/2010_conference/icaac/main.html#lib [Last accessed July 2013]
   Google Scholar
• Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012;379:2439-48
   PubMed Web of Science ®Google Scholar
• DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012;379:2429-38
   PubMed Web of Science ®Google Scholar
• German P, Warren D, West S, et al. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010;55:323-9.
   PubMed Web of Science ®Google Scholar
• Moyle G, Orkin C, Fisher M, et al. Switching to a single-tablet regimen (STR) of Atripla® (ATR) from a 2 or 3-pill combination of the individual components (efavirenz [EFV], emtricitabine [FTC] and tenofovir df [TDF]) maintains virological suppression: primary endpoint results of a 48-week, open-label study. HIV Med 2011;12(S1):79
   Web of Science ®Google Scholar
• DeJesus E, Rockstroh JK, Henry K, et al. Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF ‘QUAD’ compared to ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in treatment naïve HIV-1 infected subjects. Conference for Retroviruses and Opportunistic Infections 2012;3:211
   Google Scholar
• Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. US: Department of Health and Human Services/AIDS Info, 31st July 2012. Available at: http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf [Last accessed October 2012]
   Google Scholar
• DeJesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr 2009;51:163-74
   PubMed Web of Science ®Google Scholar
• DeJesus E, Ruane P, McDonald C. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. HIV Clin Trials 2008;9:103-14
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Johnson M, Ribera E, et al. The 5 year safety and efficacy of the once-daily antiretroviral-naïve patient regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir DF (TDF). J Int AIDS Soc 2010;13:P6
   PubMed Web of Science ®Google Scholar
• Cohen C, Wohl D, Arribas J, et al. STaR Study: single-tablet regimen emtricitabine/rilpivirine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naïve adults. J Int AIDS Soc 2012;15:18221
   Google Scholar
• Fisher M, Palella F, Tebas P, et al. SPIRIT: switching to emtricitabine/rilpivirine/tenofovir DF single-tablet regimen from boosted protease inhibitor maintains HIV suppression through week 48. J Int AIDS Soc 2012;15:18075
   Google Scholar
• Zolopa A, Sax, PE, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013;63:96-100
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Henry K, et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013;62:483-6
   PubMed Web of Science ®Google Scholar
• Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000;30:S171-6
   PubMed Web of Science ®Google Scholar
• Reis AC, Guerra M, Lencastre L. Treatment adherence, quality of life and clinical variables in HIV/AIDS infection. 10th International Congress on Drug Therapy in HIV Infection. J Int AIDS Soc 2010;13:P119
   Google Scholar
• Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother 2009;64:910-28
   PubMed Web of Science ®Google Scholar
• Sax PE, Meyers JL, Mugavero MJ, et al. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS ONE 2012;7:e31591
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19
   PubMed Web of Science ®Google Scholar
• Laurence J. Treating HIV infection with one pill per day. AIDS Patient Care and STDs 2006;20:601-3
   PubMed Web of Science ®Google Scholar
• Aragão F, Cavaco M. Benefícios da simplificação da terapêutica anti-retroviral na adesão. XI Congresso Nacional de Doenças Infeciosas e Microbiologia Clínica & IX Congresso Nacional sobre SIDA. Porto, Portugal (2012). Poster P143
   Google Scholar
• Juday T, Grimm K, Zoe-Powers A, et al. A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States. AIDS Care 2011;23:1154-62
   PubMed Web of Science ®Google Scholar
• Gianotti N, Galli L, Bocchiola B, et al. Adherence, quality of life and number of daily pills in large cross-sectional study. J Int AIDS Soc 2010;13:P116
   Google Scholar
• Edelman EJ, Gordon K, Justice AC, et al. Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir. AIDS Patient Care and STDs 2012;26:312-19
   PubMed Web of Science ®Google Scholar
• Colombo GL, Di Matteo S, Maggiolo F. Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen. ClinicoEconomics and Outcomes Research 2013;5:59-68
   PubMedGoogle Scholar
• Colombo GL, Colangeli V, Di Biagio A, et al. Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. ClinicoEconomics and Outcomes Research 2011;3:197-205
   Google Scholar
• Cohen C, Davis KL, Meyers JL. Association between daily antiretroviral pill burden and hospitalization risk in a medical population with HIV. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2011, Chicago, USA. Poster H2-791. Available at: http://www.industrycortex.com/datasheets/profile/1253880109/poster-poster-number-h2-791-51st-interscience-conference-on-ant [Last accessed July 2013]
   Google Scholar
• Cohen C, Davis KL, Meyers J. Effect of daily antiretroviral pill burden on healthcare utilization and costs in United States Medicaid enrollees with HIV. 13th European AIDS Conference (EACS) 2011, Belgrade, Serbia. Poster PE7.5/7. Available at: http://www.abstractserver.com/eacsabstractarchive/ [Last accessed July 2013]
   Google Scholar
• Colombo GL, Castagna A, Salpietro S, et al. Cost-effectiveness evaluation of initial HAART regimens for managing HIV-infected patients according to real clinical practice. J Int AIDS Soc 2012;15:18386
   Google Scholar
• Blasco AJ, Arribas JR, Clotet B. Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA para el tratamiento antirretroviral inicial. Enferm Infecc Microbiol Clin 2011;29:721-30
   PubMedGoogle Scholar
• Aldir I, Doroana M, Oliveira J, et al. Cost-efficacy of European AIDS Clinical Society recommended initial antiretroviral regimens for treatment of HIV infection in Portugal. J Int AIDS Soc 2012;15:18374
   Google Scholar
• Gouveia M, Costa J, Teófilo E, et al. Budget impact analysis of introducing a new single tablet regimen rilpivirine/emtricitabine/tenofovir for the treatment of HIV in Portugal. J Int AIDS Soc 2012;15:18375
   Google Scholar
• Shionogi-ViiV Healthcare LLC Press release. Available at: http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1177620.htm [Last accessed April 2013]
   Google Scholar